Tongcai Financial APP reported that Kangfeng Biotech-B (06922) released its performance for the six months ending June 30, 2024. The group achieved revenue...
Tongcai Financial APP reported that Kangfeng Biotech-B (06922) released its performance for the six months ending June 30, 2024. The group achieved revenue of 19.475 million yuan (RMB), an increase of 2.97% compared to the same period last year. The loss attributable to the owners of the parent company expanded by 202.2% to 52.171 million yuan, with a basic loss per share of 0.22 yuan.
The announcement stated that the revenue increased by 3.0%, mainly due to the increase in sales of the group's pulmonary nodule localization needles.
